Frequency of SOX group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters Journal Article
| Authors: | Vural, B.; Chen, L. C.; Saip, P.; Chen, Y. T.; Ustuner, Z.; Gonen, M.; Simpson, A. J. G.; Old, L. J.; Ozbek, U.; Gure, A. O. |
| Article Title: | Frequency of SOX group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters |
| Abstract: | BACKGROUND. Expression of neuroectodermal markers is a key feature of small cell lung carcinoma (SCLC). Although immune responses against a number of these proteins have been associated with paraneoplastic neuronal disease (PND), most patients with SCLC have anti-neuroectodermal antibodies in the absence of PND. Whether these immune responses affect the clinical outcome in SCLC is critical in understanding the potential value of these proteins as cancer vaccine targets as well as in the pathogenesis of PND. METHODS. The authors investigated the frequency of immunoglobulin G autoantibodies against Sry-like high-mobility group box (SOX)1, 2, 3 and Zinc-finger gene of the cerebellum (ZIC)2 proteins in stored serum samples from 90 patients utilizing the λ-phage plaque assay. Data obtained from patient records were utilized to measure clinical correlates of seroreactivity. RESULTS. Antibodies to SOX1 were present in 28% of patients and another 28% had anti-ZIC2 antibodies, classifying these as some of the most frequent antibody responses observed in SCLC. None had autoimmune paraneoplastic disease. Antibody titers were frequently as high as ≥ 1:106 and were stable for ≤ 6 months after diagnosis. Seroreactivity against either SOX1 or ZIC2 correlated with younger age, lower lactate dehydrogenase levels, and better response to initial therapy. CONCLUSIONS. The frequent and stable presence of SOX Group B and/or ZIC2 antibodies in SCLC, but not in healthy individuals examined, indicates they are serological markers of SCLC. However, the correlation between known clinical parameters of less aggressive disease and seroreactivity suggests that these antibodies are indicators of better prognosis in SCLC and warrants further studies to clarify the nature of the underlying immune responses. © 2005 American Cancer Society. |
| Keywords: | adult; cancer survival; human tissue; aged; aged, 80 and over; middle aged; unclassified drug; major clinical study; dna-binding proteins; cerebellum; demography; lung neoplasms; transcription factors; lung small cell cancer; antigens, neoplasm; immunoglobulin g; nucleotide sequence; tumor immunity; autoimmunity; turkey (republic); turkey; lactate dehydrogenase; autoantibody; autoimmune disease; zinc finger protein; l-lactate dehydrogenase; autoantibodies; serology; antibodies, neoplasm; antibody; antibody titer; carcinoma, small cell; tumor markers; virus culture; high mobility group proteins; paraneoplastic syndromes; hmgb proteins; paraneoplastic; sry like high mobility group box |
| Journal Title: | Cancer |
| Volume: | 103 |
| Issue: | 12 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2005-06-15 |
| Start Page: | 2575 |
| End Page: | 2583 |
| Language: | English |
| DOI: | 10.1002/cncr.21088 |
| PUBMED: | 15880380 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 30" - "Export Date: 24 October 2012" - "CODEN: CANCA" - "Molecular Sequence Numbers: GENBANK: NM_007129, X71135, Y13463, Z31560;" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work